Literature DB >> 10482951

A previously unrecognised phenotype characterised by obesity, muscular hypotonia, and ability to speak in patients with Angelman syndrome caused by an imprinting defect.

G Gillessen-Kaesbach1, S Demuth, H Thiele, U Theile, C Lich, B Horsthemke.   

Abstract

The clinical features of Angelman syndrome (AS) comprise severe mental retardation, postnatal microcephaly, macrostomia and prognathia, absence of speech, ataxia, and a happy disposition. We report on seven patients who lack most of these features, but presented with obesity, muscular hypotonia and mild mental retardation. Based on the latter findings, the patients were initially suspected of having Prader-Willi syndrome. DNA methylation analysis of SNRPN and D15S63, however, revealed an AS pattern, ie the maternal band was faint or absent. Cytogenetic studies and microsatellite analysis demonstrated apparently normal chromosomes 15 of biparental inheritance. We conclude that these patients have an imprinting defect and a previously unrecognised form of AS. The mild phenotype may be explained by an incomplete imprinting defect or by cellular mosaicism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482951     DOI: 10.1038/sj.ejhg.5200362

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  18 in total

1.  UBE3A Suppresses Overnutrition-Induced Expression of the Steatosis Target Genes of MLL4 by Degrading MLL4.

Authors:  Janghyun Kim; Bora Lee; Dae-Hwan Kim; Jae Gwang Yeon; Jeongkyung Lee; Younjung Park; Yuna Lee; Soo-Kyung Lee; Seunghee Lee; Jae W Lee
Journal:  Hepatology       Date:  2019-02-07       Impact factor: 17.425

2.  A mouse model of Angelman syndrome imprinting defects.

Authors:  Michael W Lewis; Dorianmarie Vargas-Franco; Deborah A Morse; James L Resnick
Journal:  Hum Mol Genet       Date:  2019-01-15       Impact factor: 6.150

3.  An atypical case of hypomethylation at multiple imprinted loci.

Authors:  Emma L Baple; Rebecca L Poole; Sahar Mansour; Catherine Willoughby; I Karen Temple; Louise E Docherty; Rohan Taylor; Deborah J G Mackay
Journal:  Eur J Hum Genet       Date:  2011-01-05       Impact factor: 4.246

4.  Distinct phenotypes distinguish the molecular classes of Angelman syndrome.

Authors:  A C Lossie; M M Whitney; D Amidon; H J Dong; P Chen; D Theriaque; A Hutson; R D Nicholls; R T Zori; C A Williams; D J Driscoll
Journal:  J Med Genet       Date:  2001-12       Impact factor: 6.318

Review 5.  The human imprintome: regulatory mechanisms, methods of ascertainment, and roles in disease susceptibility.

Authors:  David A Skaar; Yue Li; Autumn J Bernal; Cathrine Hoyo; Susan K Murphy; Randy L Jirtle
Journal:  ILAR J       Date:  2012

Review 6.  Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms.

Authors:  Renzo Guerrini; Romeo Carrozzo; Roberta Rinaldi; Paolo Bonanni
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

7.  Practice guidelines for the molecular analysis of Prader-Willi and Angelman syndromes.

Authors:  Simon C Ramsden; Jill Clayton-Smith; Rachael Birch; Karin Buiting
Journal:  BMC Med Genet       Date:  2010-05-11       Impact factor: 2.103

8.  Beckwith-Wiedemann syndrome and pseudohypoparathyroidism type Ib in a patient with multilocus imprinting disturbance: a female-dominant phenomenon?

Authors:  Shinichiro Sano; Keiko Matsubara; Keisuke Nagasaki; Toru Kikuchi; Kazuhiko Nakabayashi; Kenichiro Hata; Maki Fukami; Masayo Kagami; Tsutomu Ogata
Journal:  J Hum Genet       Date:  2016-04-28       Impact factor: 3.172

9.  Epimutations in Prader-Willi and Angelman syndromes: a molecular study of 136 patients with an imprinting defect.

Authors:  Karin Buiting; Stephanie Gross; Christina Lich; Gabriele Gillessen-Kaesbach; Osman el-Maarri; Bernhard Horsthemke
Journal:  Am J Hum Genet       Date:  2003-01-23       Impact factor: 11.025

Review 10.  Angelman syndrome: a review of the clinical and genetic aspects.

Authors:  J Clayton-Smith; L Laan
Journal:  J Med Genet       Date:  2003-02       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.